EVFM earnings analysis
What we found in EVFM's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Evofem Biosciences reported a modest increase in revenue and demonstrated significant improvements in operating cash flow for the first quarter of 2026 compared to the same period last year. Efforts to expand the commercial reach of its products PHEXX and SOLOSEC are ongoing, though the company faces liquidity challenges with only $2.4 million in cash on hand.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Growth
- Net product sales increased to $899K, up 6% from $845K year-over-year.
- Improvement in Gross Margin
- Gross margin for 2026Q1 improved to 61.5% compared to 60.3% in 2025Q1.
- Operating Cash Flow Surge
- Net cash provided by operating activities rose to $2.3M, a 311% increase from $0.56M in the prior year.
- Segment Expansion Initiatives
- New distribution agreement for SOLOSEC in sub-Saharan Africa adds growth potential.
- Significant Decrease in R&D Expenses
- R&D expenses decreased from $5.05M in 2025Q1 to $518K in 2026Q1, a reduction of over 90%.
- Cash Position Maintained
- Cash and cash equivalents totaled $2.4M, although insufficient for upcoming operational needs.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Liquidity Concerns
- The company has a working capital deficit of $72.7M as of March 31, 2026.
- Dependence on Continuous Funding
- Cash on hand is insufficient to fund operations for the next 12 months.
- Market Adoption Risks
- Sales momentum for PHEXX may be impacted by decreased wholesaler purchases prior to price changes.
What they reported.
What the company itself reported, taken out of the document.
- Gross margin
- 61.5%
What they said about what is next.
Management anticipates revenue growth through enhanced marketing and sales strategies in 2026.
The filing reads about the same as the one before it.
What came before.
- 10-K · March 11, 2026
- Evofem is a commercial-stage women’s sexual and reproductive health company marketing PHEXX (FDA approved May 22, 2020; launched Sept 2020) and SOLOSEC (global rights acquired July 14, 2024; relaunched Nov 2024). Q4…
- 10-Q · November 13, 2025
- Evofem reported quarterly product revenue of $4,952,000 (up from $4,496,000 in Q3 2024) and produced operating income of $951,000 for the three months ended September 30, 2025, a swing from an operating loss of…
- 10-Q · August 14, 2025
- Evofem reported Q2 product sales of $4.825M (up $0.665M, +16.0% vs. Q2 2024) and GAAP diluted loss per share of $(0.02). Gross margin expanded to ~84.3% while operating margin deteriorated to -25.9% due to $6.076M of…
- 10-Q · May 15, 2025
- Evofem reported Q1 2025 product sales of $845,000 and turned to net income of $956,000 (basic EPS $0.01; diluted $0.00), versus a net loss of $(4,809,000) in Q1 2024. Revenue fell materially versus prior-year Q1…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing EVFM makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever